TREX1 Deficiency Triggers Cell-Autonomous Immunity in a cGAS-Dependent Manner

Abstract Cytosolic detection of DNA is crucial for the initiation of antiviral immunity but can also cause autoimmunity in the context of endogenous nucleic acids being sensed. Mutations in the human 3′ repair exonuclease 1 (TREX1) have been linked to the type I IFN–associated autoimmune disease Aicardi–Goutières syndrome. The exact mechanisms driving unabated type I IFN responses in the absence of TREX1 are only partly understood, but it appears likely that accumulation of endogenous DNA species triggers a cell-autonomous immune response by activating a cytosolic DNA receptor. In this article, we demonstrate that knocking out the DNA sensor cyclic GMP–AMP synthase completely abrogates spontaneous induction of IFN-stimulated genes in TREX1-deficient cells. These findings indicate a key role of cyclic GMP–AMP synthase for the initiation of self-DNA–induced autoimmune disorders, thus providing important implications for novel therapeutic approaches.</jats:p

Efficient production of inhibitor-free foamy virus glycoprotein-containing retroviral vectors by proteoglycan-deficient packaging cells

Foamy viruses (FVs) or heterologous retroviruses pseudotyped with FV glycoprotein enable transduction of a great variety of target tissues of disparate species. Specific cellular entry receptors responsible for this exceptionally broad tropism await their identification. Though, ubiquitously expressed heparan sulfate proteoglycan (HS-PG) is known to serve as an attachment factor of FV envelope (Env)-containing virus particles, greatly enhancing target cell permissiveness. Production of high-titer, FV Env-containing retroviral vectors is strongly dependent on the use of cationic polymer-based transfection reagents like polyethyleneimine (PEI). We identified packaging cell-surface HS-PG expression to be responsible for this requirement. Efficient release of FV Env-containing virus particles necessitates neutralization of HS-PG binding sites by PEI. Remarkably, remnants of PEI in FV Env-containing vector supernatants, which are not easily removable, negatively impact target cell transduction, in particular those of myeloid and lymphoid origin. To overcome this limitation for production of FV Env-containing retrovirus supernatants, we generated 293T-based packaging cell lines devoid of HS-PG by genome engineering. This enabled, for the first, time production of inhibitor-free, high-titer FV Env-containing virus supernatants by non-cationic polymer-mediated transfection. Depending on the type of virus, produced titers were 2- to 10-fold higher compared with those obtained by PEI transfection

T cell derived IL-10 is dispensable for tolerance induction in a murine model of allergic airway inflammation

Regulatory mechanisms initiated by allergen specific immunotherapy are mainly attributed to T cell-derived IL-10. However, it has not been shown that T cell-derived IL-10 is required for successful tolerance induction. Here, we analyze cellular sources and the functional relevance of cell type specific IL-10 during tolerance induction in a murine model of allergic airway inflammation. While tolerance induction was effective in IL-10 competent mice, neutralizing IL-10 prior to tolerogenic treatment completely abrogated the beneficial effects. Cellular sources of IL-10 during tolerance induction were identified by using transcriptional reporter mice as T cells, B cells and to a lesser extent DCs. Interestingly, tolerance induction was still effective in mice with T cell-, B cell-, B and T cell- or DC-specific IL-10 deficiency. In contrast, tolerance induction was not possible in mice lacking IL-10 in all hematopoetic cells, while it was effective in bone marrow chimera that lacked IL-10 only in non-hematopoetic cells. Taken together, allergen specific tolerance depends on IL-10 from hematopoetic sources. The beneficial effects of allergen specific immunotherapy cannot solely be attributed to IL-10 from T cells, B cells or even DCs, suggesting a high degree of cellular redundancy in IL-10 mediated tolerance

Loss of Trex1 in Dendritic Cells Is Sufficient To Trigger Systemic Autoimmunity

Defects of the intracellular enzyme 3' repair exonuclease 1 (Trex1) cause the rare autoimmune condition Aicardi-Goutières syndrome and are associated with systemic lupus erythematosus. Trex1(-/-) mice develop type I IFN-driven autoimmunity, resulting from activation of the cytoplasmic DNA sensor cyclic GMP-AMP synthase by a nucleic acid substrate of Trex1 that remains unknown. To identify cell types responsible for initiation of autoimmunity, we generated conditional Trex1 knockout mice. Loss of Trex1 in dendritic cells was sufficient to cause IFN release and autoimmunity, whereas Trex1-deficient keratinocytes and microglia produced IFN but did not induce inflammation. In contrast, B cells, cardiomyocytes, neurons, and astrocytes did not show any detectable response to the inactivation of Trex1. Thus, individual cell types differentially respond to the loss of Trex1, and Trex1 expression in dendritic cells is essential to prevent breakdown of self-tolerance ensuing from aberrant detection of endogenous DNA

Ribonucleotide excision repair is essential to prevent squamous cell carcinoma of the skin

Due to imperfect discrimination against ribonucleoside triphosphates by the replicative DNA polymerases, large numbers of ribonucleotides are incorporated into the eukaryotic nuclear genome during S-phase. Ribonucleotides, by far the most common DNA lesion in replicating cells, destabilize the DNA, and an evolutionarily conserved DNA repair machinery, ribonucleotide excision repair (RER), ensures ribonucleotide removal. Whereas complete lack of RER is embryonically lethal, partial loss-of-function mutations in the genes encoding subunits of RNase H2, the enzyme essential for initiation of RER, cause the SLE-related type I interferonopathy Aicardi-Goutières syndrome. Here we demonstrate that selective inactivation of RER in mouse epidermis results in spontaneous DNA damage and epidermal hyperproliferation associated with loss of hair follicle stem cells and hair follicle function. The animals developed keratinocyte intraepithelial neoplasia and invasive squamous cell carcinoma with complete penetrance, despite potent type I interferon production and skin inflammation. These results suggest that compromises to RER-mediated genome maintenance might represent an important tumor-promoting principle in human cancer.</p

NIS-Seq enables cell-type-agnostic optical perturbation screening

Optical pooled screening offers a broader-scale alternative to enrichment-based perturbation screening, using fluorescence microscopy to correlate phenotypes and perturbations across single cells. Previous methods work well in large, transcriptionally active cell lines, because they rely on cytosolic detection of endogenously expressed barcoded transcripts; however, they are limited by reliable cell segmentation, cytosol size, transcriptional activity and cell density. Nuclear In-Situ Sequencing (NIS-Seq) expands this technology by creating bright sequencing signals directly from nuclear genomic DNA to screen nucleated cells at high density and high library complexity. By inserting an inverted phage promoter downstream of the single guide RNA (sgRNA), many RNA copies of the sgRNA can be generated and sequenced independently of cellular transcription. In this study, we benchmarked NIS-Seq across eight cell types from two species and performed four genome-scale optical perturbation screens, identifying key players of inflammation-related cellular pathways. Finally, we performed a small-scale pooled optical screen in primary human macrophages from blood of healthy donors and demonstrated barcode identification in lentivirally transduced human skin tissue

Immunogene und immunsuppressive Eigenschaften des transmembranen Hüllproteins gp41 von HIV

Die Entwicklung eines effektiven HIV-Impfstoffes ist bis heute nicht gelungen.Konventionelle Immunisierungsstrategien mit rekombinant hergestellten Hüllproteinen des Virus in verschiedensten Formen induzierten keine subtypenübergreifende, protektive Immunantwort gegen HIV. Die Gewinnung und Charakterisierung der gp41-spezifischen breit neutralisierenden monoklonalen Antikörper 2F5 und 4E10 bildete die Grundlage einer Reihe neuer epitopgerichteter Ansätze für die HIV-Impfstoffentwicklung. Bisherige Immunisierungsstudien basierten auf der Verwendung des linearen Hauptepitopes (E2) der beiden Antikörper aus dem C-terminalen Teil der Ektodomäne von gp41. Nach neueren Erkenntnissen, reicht für eine effektive Neutralisation durch 2F5 oder 4E10 die Bindung dieser Antikörper an ihr lineares Epitop in der membran proximalen externen Region (MPER) von gp41 allein nicht aus. Vielmehr wurde die Beteiligung einer N-terminalen Domäne (E1) von gp41 an der neutralisationsaktiven Bindung von 2F5 bzw. 4E10 postuliert. In dieser Arbeit wurden die beiden 2F5 und 4E10 spezifischen Epitopbereiche E1 und E2 des gp41 erstmals in das strukturell verwandte transmembrane Hüllprotein des Koala Retrovirus (KoRV) eingebracht. Die Applikation der hergestellten Antigene erfolgte sowohl in Form der codierenden DNA mittels ballistischer Immunisierung (GeneGun®) als auch durch bakteriell exprimierte Proteine. Mit beiden Strategien konnten für drei Hybridproteine in den ersten Studien eine HIV-1 gp41 spezifische, breit neutralisierende humorale Immunantwort induziert werden. Diese Ergebnisse konnten jedoch in späteren Studien nicht reproduziert werden. Die Analyse der induzierten Immunantworten zeigte eine Verlagerung der Hauptimmunantwort als deren Ursache eine bakterielle Fremdinfektion der Versuchtiere diskutiert wurde. Zur Evaluierung der Immunisierungsstudien wurde ein neuartiger real time PCR basierter in vitro Neutralisationstest um Kontrollen zur Virusspezifität und Cytotoxizität erweitert.The development of an effective HIV vaccine is considered the to play a key role in controlling the HIV pandemic. Conventional immunisation strategies using recombinant envelope proteins of the virus did not lead to the induction of a broad range protective immunity. A new target sequence for the induction of a broadly neutralising humoral immune response has been discovered through the characterization of the gp41 specific broadly neutralising monoclonal antibodies 2F5 and 4E10. Until now all attempts to induce 2F5/4E10 like neutralising antibodies failed. So far only the linear main epitope (E2) of 2F5 and 4E10, located in the C-terminal part of the gp41 ectodomain was used as the target sequence. However, it was recently shown that an N-terminal domain (E1) of gp41 increases the avidity of 2F5 to its epitope. The E1 domain may therefore be involved in the mediation of a neutralisation active binding. For the first time immunisation strategies have been developed that target both previously identified domains (E1 and E2) of gp41. The sequences corresponding to E1 and E2 have been introduced at homologous positions in the structurally related transmembrane envelope protein p15E of the Koala Retrovirus (KoRV). These generated hybrid antigens have been used for immunisation of wistar rats. They were applied as recombinant proteins expressed in E.coli and as DNA using a ballistic immunisation (GeneGun®) approach. Although in first trials neutralising antibodies specific for gp41 of HIV-1 were induced, these results could not be reproduced. Analysis of the induced antibodies showed a shift of their binding specifity. A bacterial infection of the used animals was identified as the cause of the unexpected shift in the antigen specific humoral immune response. For evaluation of the immunisation studies a new neutralisation assay based on the measurement of provirus integration by duplex real time PCR has been extended for controls of virus specifity and cytotoxicity

Tiermodelle zur Erforschung von SARS-CoV-2 und COVID-19

Während des letzten Jahres breitete sich das neuartige Coronavirus SARS-CoV-2 weltweit rasant aus. In einem Teil der Infizierten verursacht das Virus die COVID-19-Erkrankung, die durch Lungenentzündung und neurologische Symptome gekennzeichnet ist. Bei Risikopatienten kann die Infektion zu tödlichen Komplikationen führen, womit SARS-CoV-2 angesichts der hohen Zahl an Infizierten global als eine sehr ernst zu nehmende Bedrohung für die Gesundheit der Menschen und unsere sozialen Systeme einzuschätzen ist. Die Entwicklung sicherer und wirksamer antiviraler Medikamente gegen SARS-CoV-2 und hilfreicher Therapien für Infizierte erfordert das Studium des Erregers in adäquaten Tiermodellen. SARS-CoV-2 nutzt das Angiotensin Converting Enzyme 2 (ACE2) als Eintrittsrezeptor. Die Stärke der Bindung von SARS-CoV-2 an das ACE2-Protein entscheidet darüber, wie effizient das Virus eine Spezies infizieren kann, und ob die Infektion Krankheitssymptome auslöst, die das jeweilige Tier als Modellorganismus qualifizieren. Mäuse, als eine der wichtigsten Laborspezies, eignen sich nur nach gentechnischen Veränderungen der Maus oder des Virus als Modell für SARS-CoV-2. Dafür stellen Hamster, Frettchen und Rhesusaffen sehr wichtige Tiermodelle dar, weil diese nach Infektion mit SARS-CoV-2 relevante Aspekte von COVID-19 abbilden. Verschiedene Vakzin-Kandidaten wurden z. B. in Rhesusaffen getestet und lieferten vielversprechende Ergebnisse. Zusammenfassend steht der Forschung bereits eine Reihe nützlicher Tiermodelle zur Verfügung, die schon jetzt entscheidende Beiträge zur Entwicklung von Vakzinen gegen SARS-CoV-2 und neuer Therapien für COVID-19 geleistet haben.</jats:p